
AxoGen, Inc.
AXGNNASDAQHealthcareMedical - Devices
Latest quote
$50.36
+$3.96 · +8.53%
AXGN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
73
Undervalued
Momentum
74
Gaining
Sentiment
63
Bullish
Risk resilience
56
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Michael D. Dale
- Listed since
- Dec 17, 1986
- Employees
- 622
Market position
- Volume
- 1.78M
- 1.48× average
- Average volume
- 1.21M
- Average daily volume
- Market cap
- 2.71B USD
- Beta
- 1.14
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.54B USD
- EV / EBITDA
- 8,017.22×
- Earnings yield
- -1.04%
- Free cash flow yield
- -0.19%
Profitability & efficiency
- Return on equity
- -12.19%
- Return on assets
- -7.08%
- Return on invested capital
- -3.91%
Financial health
- Current ratio
- 5.11×
- Altman Z-score
- 33.2
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 225.21M USD | 187.34M USD | 159.01M USD | 138.58M USD | 127.36M USD |
| Cost of goods sold | 57.86M USD | 45.36M USD | 37.14M USD | 29.78M USD | 22.93M USD |
| Gross profit | 167.35M USD | 141.98M USD | 121.87M USD | 108.81M USD | 104.43M USD |
| Research and development | 32.89M USD | 27.77M USD | 27.34M USD | 25.63M USD | 24.18M USD |
| Selling, general, and administrative | 142.32M USD | 117.5M USD | 115.99M USD | 112.89M USD | 105.67M USD |
| Operating expenses | 175.2M USD | 145.26M USD | 143.33M USD | 138.52M USD | 129.84M USD |
| Interest expense | 7.7M USD | 8.21M USD | 2.84M USD | 624K USD | 1.36M USD |
| Depreciation and amortization | 8.19M USD | 7.84M USD | 5.55M USD | 4.85M USD | 4.74M USD |
| Operating income | −7.85M USD | −3.29M USD | −21.46M USD | −29.71M USD | −25.42M USD |
| Net income | −15.7M USD | −9.96M USD | −21.72M USD | −28.95M USD | −26.99M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 64%
- 7 beats, 4 misses, 0 met estimates
- Average EPS surprise
- +128.12%
- 11 comparable reports
- Latest EPS result
- 0.12
- Estimate 0.12 · Miss by 1.15%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$52.20
3.57% upsideRating distribution
19 ratingsRecent analyst actions
AXGN news
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$1.00
2010 complete year+2296.8% since 1992
$0.0417
1,992
$0.06
2,005
$1.00
2,010
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jan 27, 2010 | $1.00Special | Jan 29, 2010 | Feb 12, 2010 |
Dividend | Feb 23, 2005 | $0.06Special | — | — |
Dividend | Jul 10, 1992 | $0.0417Special | — | — |
Ex-dividend Jan 27, 2010
$1.00
Special
Record Jan 29, 2010 · Payment Feb 12, 2010
Ex-dividend Feb 23, 2005
$0.06
Special
Ex-dividend Jul 10, 1992
$0.0417
Special
AXGN peers
Continue in GoAI
Research AXGNresearch.disclaimer











